This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 either as a single or multiple dose in adult patients with obstructive hypertrophic cardiomyopathy.
Male or nonpregnant female, age ≥18 years. Body mass index (BMI) ≥18 to <35 kg/m2; weight ≥50 kg at Screening. Diagnosed with HCM at the time of Screening consistent with current American College of Cardiology Foundation/American Heart Association Guidelines LVOT peak gradient ≥30 mmHg measured at rest and ≥50 mmHg post-Valsalva as determined by echocardiography at Screening. Documented left ventricular ejection fraction (LVEF) ≥0.60 at Screening. New York Heart Association (NYHA) Classification I-III at Screening.
Key Exclusion Criteria:
Invasive septal reduction <180 days prior to Screening. Documented current or history of obstructive coronary artery disease at any time or myocardial infarction <180 days prior to Screening. Known Stage B or higher aortic valve stenosis or regurgitation A history of syncope or sustained ventricular tachyarrhythmia <180 days prior to Screening. A history of sudden cardiac arrest at any time or known appropriate implantable cardioverter defibrillator (ICD) discharge <180 days prior to Screening Atrial fibrillation (AF) at Screening; a current diagnosis of permanent AF; paroxysmal or persistent AF <90 days of Screening, or electrical cardioversion or ablation for AF <90 days of Screening. Fridericia-corrected QT interval (QTcF) ≥480 ms or any other ECG abnormality considered by the Investigator to pose a risk to participant safety. Current or prior use of any cardiac myosin inhibitors
